Literature DB >> 26968206

Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC.

Andrew Gabrielson1, Yunan Wu2, Hongkun Wang1, Jiji Jiang1, Bhaskar Kallakury3, Zoran Gatalica4, Sandeep Reddy4, David Kleiner5, Thomas Fishbein6, Lynt Johnson7, Eddie Island6, Rohit Satoskar6, Filip Banovac8, Reena Jha8, Jaydeep Kachhela1, Perry Feng1, Tiger Zhang1, Anteneh Tesfaye1, Petra Prins1, Christopher Loffredo1, John Marshall1, Louis Weiner1, Michael Atkins1, Aiwu Ruth He9.   

Abstract

Immune cells that infiltrate a tumor may be a prognostic factor for patients who have had surgically resected hepatocellular carcinoma (HCC). The density of intratumoral total (CD3(+)) and cytotoxic (CD8(+)) T lymphocytes was measured in the tumor interior and in the invasive margin of 65 stage I to IV HCC tissue specimens from a single cohort. Immune cell density in the interior and margin was converted to a binary score (0, low; 1, high), which was correlated with tumor recurrence and relapse-free survival (RFS). In addition, the expression of programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) was correlated with the density of CD3(+) and CD8(+) cells and clinical outcome. High densities of both CD3(+) and CD8(+) T cells in both the interior and margin, along with corresponding Immunoscores, were significantly associated with a low rate of recurrence (P = 0.007) and a prolonged RFS (P = 0.002). In multivariate logistic regression models adjusted for vascular invasion and cellular differentiation, both CD3(+) and CD8(+) cell densities predicted recurrence, with odds ratios of 5.8 [95% confidence interval (CI), 1.6-21.8] for CD3(+) and 3.9 (95% CI, 1.1-14.1) for CD8(+) Positive PD-L1 staining was correlated with high CD3 and CD8 density (P = 0.024 and 0.005, respectively) and predicted a lower rate of recurrence (P = 0.034), as well as prolonged RFS (P = 0.029). Immunoscore and PD-L1 expression, therefore, are useful prognostic markers in patients with HCC who have undergone primary tumor resection. Cancer Immunol Res; 4(5); 419-30. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26968206      PMCID: PMC5303359          DOI: 10.1158/2326-6066.CIR-15-0110

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  40 in total

1.  Effector memory T cells, early metastasis, and survival in colorectal cancer.

Authors:  Franck Pagès; Anne Berger; Matthieu Camus; Fatima Sanchez-Cabo; Anne Costes; Robert Molidor; Bernhard Mlecnik; Amos Kirilovsky; Malin Nilsson; Diane Damotte; Tchao Meatchi; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Jérôme Galon
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

Review 2.  Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies.

Authors:  Imke Atreya; Markus F Neurath
Journal:  Expert Rev Anticancer Ther       Date:  2008-04       Impact factor: 4.512

3.  Ectopic lymph nodes within human solid tumors.

Authors:  Domenico Coppola; James J Mulé
Journal:  J Clin Oncol       Date:  2008-09-20       Impact factor: 44.544

4.  Vascular invasion leaves its mark in hepatocellular carcinoma.

Authors:  Aileen Marshall; Graeme Alexander
Journal:  J Hepatol       Date:  2011-05-20       Impact factor: 25.083

5.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.

Authors:  Y Naito; K Saito; K Shiiba; A Ohuchi; K Saigenji; H Nagura; H Ohtani
Journal:  Cancer Res       Date:  1998-08-15       Impact factor: 12.701

6.  Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells.

Authors:  Axel C P Diederichsen; J v B Hjelmborg; Per B Christensen; Jesper Zeuthen; Claus Fenger
Journal:  Cancer Immunol Immunother       Date:  2003-04-15       Impact factor: 6.968

7.  Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes.

Authors:  Shimul A Shah; Sean P Cleary; Alice C Wei; Ilun Yang; Bryce R Taylor; Alan W Hemming; Bernard Langer; David R Grant; Paul D Greig; Steven Gallinger
Journal:  Surgery       Date:  2006-11-01       Impact factor: 3.982

Review 8.  An immunologic portrait of cancer.

Authors:  Maria Libera Ascierto; Valeria De Giorgi; Qiuzhen Liu; Davide Bedognetti; Tara L Spivey; Daniela Murtas; Lorenzo Uccellini; Ben D Ayotte; David F Stroncek; Lotfi Chouchane; Masoud H Manjili; Ena Wang; Francesco M Marincola
Journal:  J Transl Med       Date:  2011-08-29       Impact factor: 5.531

9.  Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy.

Authors:  Stéphane Champiat; Charles Ferté; Sophie Lebel-Binay; Alexander Eggermont; Jean Charles Soria
Journal:  Oncoimmunology       Date:  2014-01-16       Impact factor: 8.110

10.  EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation.

Authors:  Hanane Lanaya; Anuradha Natarajan; Karin Komposch; Liang Li; Nicole Amberg; Lei Chen; Stefanie K Wculek; Martina Hammer; Rainer Zenz; Markus Peck-Radosavljevic; Wolfgang Sieghart; Michael Trauner; Hongyang Wang; Maria Sibilia
Journal:  Nat Cell Biol       Date:  2014-08-31       Impact factor: 28.824

View more
  116 in total

Review 1.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

2.  Genomic and transcriptional Profiling of tumor infiltrated CD8+ T cells revealed functional heterogeneity of antitumor immunity in hepatocellular carcinoma.

Authors:  Zhenli Li; Geng Chen; Zhixiong Cai; Xiuqing Dong; Liman Qiu; Haipo Xu; Yongyi Zeng; Xiaolong Liu; Jingfeng Liu
Journal:  Oncoimmunology       Date:  2018-11-10       Impact factor: 8.110

Review 3.  Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma.

Authors:  Michihisa Moriguchi; Atsushi Umemura; Yoshito Itoh
Journal:  Clin J Gastroenterol       Date:  2016-07-11

Review 4.  T lymphocytes in hepatocellular carcinoma immune microenvironment: insights into human immunology and immunotherapy.

Authors:  Jin Bian; Jianzhen Lin; Junyu Long; Xu Yang; Xiaobo Yang; Xin Lu; Xinting Sang; Haitao Zhao
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

5.  Tumor-Infiltrating Lymphocytes and Macrophages in Intrahepatic Cholangiocellular Carcinoma. Impact on Prognosis after Complete Surgery.

Authors:  Luca Vigano; Cristiana Soldani; Barbara Franceschini; Matteo Cimino; Ana Lleo; Matteo Donadon; Massimo Roncalli; Alessio Aghemo; Luca Di Tommaso; Guido Torzilli
Journal:  J Gastrointest Surg       Date:  2019-01-31       Impact factor: 3.452

Review 6.  Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment.

Authors:  Amblessed E Onuma; Hongji Zhang; Hai Huang; Terence M Williams; Anne Noonan; Allan Tsung
Journal:  Gene Expr       Date:  2020-04-27

7.  Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.

Authors:  Jingying Zhou; Man Liu; Hanyong Sun; Yu Feng; Liangliang Xu; Anthony W H Chan; Joanna H Tong; John Wong; Charing Ching Ning Chong; Paul B S Lai; Hector Kwong-Sang Wang; Shun-Wa Tsang; Tyler Goodwin; Rihe Liu; Leaf Huang; Zhiwei Chen; Joseph Jy Sung; King Lau Chow; Ka Fai To; Alfred Sze-Lok Cheng
Journal:  Gut       Date:  2017-09-22       Impact factor: 23.059

8.  Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapy.

Authors:  Dan Ou; Julien Adam; Ingrid Garberis; Pierre Blanchard; France Nguyen; Antonin Levy; Odile Casiraghi; Philippe Gorphe; Ingrid Breuskin; François Janot; Stephane Temam; Jean-Yves Scoazec; Eric Deutsch; Yungan Tao
Journal:  Oncoimmunology       Date:  2017-07-05       Impact factor: 8.110

9.  TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade.

Authors:  V Cervera-Carrascon; M Siurala; J M Santos; R Havunen; S Tähtinen; P Karell; S Sorsa; A Kanerva; A Hemminki
Journal:  Oncoimmunology       Date:  2018-04-09       Impact factor: 8.110

10.  Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma.

Authors:  Kohei Shigeta; Meenal Datta; Tai Hato; Shuji Kitahara; Ivy X Chen; Aya Matsui; Hiroto Kikuchi; Emilie Mamessier; Shuichi Aoki; Rakesh R Ramjiawan; Hiroki Ochiai; Nabeel Bardeesy; Peigen Huang; Mark Cobbold; Andrew X Zhu; Rakesh K Jain; Dan G Duda
Journal:  Hepatology       Date:  2019-10-14       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.